BioSpace News Archive

BioLife Solutions Inc. and SAVSU Technologies announced that the USPTO has issued a notice of allowance for a second patent application titled “Biologic Stability, Delivery Logistics and Administration of Time and/or Temperature Sensitive Biologic Based Materials”.

DarioHealth Corp. announced that the United States Food and Drug Administration (FDA) has granted Pre-market Notification (510(k)) clearance for the Company’s Lightning®-enabled version of the acclaimed Dario™ Blood Glucose Monitoring System which enables the use of the Dario app on iPhone 7, 8 and X smart mobile devices (SMD).

MedPharm Ltd., a leading provider of contract topical and transdermal product design and formulation development services, is pleased to announce an investment by Ampersand Capital Partners.

Eiger BioPharmaceuticals, Inc. announced the first patient dosed in PREVENT, a Phase 2, multi-center study of subcutaneous (SC) exendin 9-39 in post-bariatric surgical patients who experience dangerously low, postprandial blood glucose levels (hypoglycemia) known as post-bariatric hypoglycemia (PBH).

The myBioness is the first mobile app designed to provide control of the L300 Go™ System.

Emmaus Life Sciences (Emmaus) announced today it has opened an office in Midtown Manhattan to support the commercial launch of EndariTM (L-glutamine oral powder).